{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"1.0","value":"0.75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Time to progression (TTP) is defined as the time from protocol therapy initiation until documented progression, censored at date last known progression-free for those who have not progressed, up to 24 months post initiation of therapy.","dispersionType":"90% Confidence Interval","groups":[{"description":"* A treatment cycle is defined as 28 consecutive days.\n* Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months.\n\nNivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and\n\nLenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12\n\nDexamethasone: Oral, Days 1, 8, 15 of cycle 1-6","id":"OG000","title":"Nivolumab, Lenalidomide, Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline to documented progression, up to 24 months post initiation of therapy.","title":"Time to Progression Probability at 2-years","type":"SECONDARY","unitOfMeasure":"probability"}